

New Hampshire AIDS Drug Assistance Program Prior Authorization Drug Approval Form

Calcitonin Gene-Related Peptide (CGRP) Inhibitors for Migraine and Cluster Headache

DATE OF MEDICATION REQUEST: / /

SECTION I: PATIENT INFORMATION AND MEDICATION F	EQUESTED													
LAST NAME:	FIRST NAME:													
MEDICAID ID NUMBER:	DATE OF BIRTH:													
GENDER: Male Female Drug Name:	Strength:													
Dosing Directions:	Length of Therapy:													
SECTION II: PRESCRIBER INFORMATION														
LAST NAME:	FIRST NAME:													
SPECIALTY:	NPI NUMBER:													
PHONE NUMBER:	FAX NUMBER:													
SECTION III: CLINICAL HISTORY														
Does the patient have a diagnosis of migraine, with or Classification of Headache Disorders (ICHD-III) diagnosis														
2. Does the patient have a diagnosis of episodic cluster have criteria?	eadache based on ICHD-III diagnostic Yes No													

(Form continues on the next page.)





New Hampshire AIDS Drug Assistance Program Prior Authorization Drug Approval Form

Calcitonin Gene-Related Peptide (CGRP) Inhibitors for Migraine and Cluster Headache

DATE OF MEDICATION REQUEST: / /

PATIENT LAST NAME:													PATIENT FIRST NAME:														
SI	SECTION III: CLINICAL HISTORY (CONTINUED)																										
Fo	For prevention of migraine headaches, please answer questions 3–5.																										
3.	Has medication overuse headache been ruled out by trial and failure of titrating off acute migraine treatments in the past?														[Y	es	☐ No									
4.	On average, how many migraine days per month has the patient had for the past three months?																										
 5. Has the patient tried and failed a 1-month or longer trial of any one of the following oral medications or has the patient had a contraindication to any one of the following oral medications? antidepressants (e.g., amitriptyline, venlafaxine) beta blockers (e.g., propranolol, metoprolol, timolol, atenolol) anti-epileptics (e.g., valproate, topiramate) angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan) If yes, please list treatment failures and provide dates: 															Y	es	□ No										
6.	For	Nurte	c® OD	То	r Q	ulip	ota⁺	M: Ha	as th	e pat	tient	tried	and	d fail	ed at	leas	t o	ne ir	nject	abl	e CG	iRP?			Y	es	☐ No
Fo	r pre	ventio	n of o	lus	ter	hea	ada	ches	, ple	ase a	answ	er qu	est	ions	7–8.												
7.	Have	e othe	r ICH	D-III	l he	eada	ache	es be	en r	uled	out?														Y	es	☐ No
8.	 Has the patient tried and failed a one-month or longer trial of any two of the following oral medications or has the patient had a contraindication to any two of the following oral medications? suboccipital steroid injections lithium verapamil warfarin melatonin If yes, please list treatment failures and provide dates: 														Y	es	□ No										

(Form continues on the next page.)

Phone: 1-800-424-7901 **Fax**: 1-800-424-7984





New Hampshire AIDS Drug Assistance Program Prior Authorization Drug Approval Form

Calcitonin Gene-Related Peptide (CGRP) Inhibitors for Migraine and Cluster Headache

DATE OF MEDICATION REQUEST: / /

PATIENT LAST NAME:													PATIENT FIRST NAME:												
SEC	SECTION III: CLINICAL HISTORY (CONTINUED)																								
For	or treatment of migraine headaches, please answer questions 9–11.																								
9. (9. On average, how many migraine days per month has the patient had for the past 6 months?																								
 10. Has the patient tried and failed one or more of the following: non-steroidal anti-inflammatory drugs (NSAIDs) non-opioid analgesics acetaminophen caffeinated analgesic combination If yes, please list the treatment failures and provide dates: 														No											
11. Has the patient tried and failed one or more preferred triptan? If yes , please list the treatment failures and provide dates:															Yes		No								
SEC	TIO	N IV	: FOR	RENE	WAI	LS ON	NLY																		
			patier aches?		mons	strate	ed a	signi	fican	t dec	reas	e i	in the	num	nber,	frequ	iency	/, or	inten	sity		Yes		No	
13.	Has	the	patier	nt had	d an	over	all im	nprov	/eme	nt in	fund	ti	on wi	th th	erap	y?						Yes		No	
14.	Has	the	patier	nt exp	oerie	nced	any	unad	cept	able	toxio	cit	y?									Yes		No	
Provide any additional information that would help in the decision-making process. If additional space is needed, please use another page.																									
I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability. PRESCRIBER'S SIGNATURE:																									
																		_							

Phone: 1-800-424-7901 **Fax**: 1-800-424-7984

